Rangwala Reshma 4
4 · Karyopharm Therapeutics Inc. · Filed Feb 3, 2026
Research Summary
AI-generated summary of this filing
Karyopharm (KPTI) CMO Reshma Rangwala Receives RSU Award
What Happened
- Reshma Rangwala, Executive Vice President & Chief Medical Officer of Karyopharm Therapeutics Inc. (KPTI), received a grant of 32,415 restricted stock units (RSUs) on January 31, 2026. The Form 4 reports the award as an acquisition (transaction code A) at $0.00 per share (RSUs are awards, not purchases).
Key Details
- Transaction date: 2026-01-31; Filing date (Accession): 2026-02-03.
- Transaction type/code: Award/Grant (A).
- Shares/units granted: 32,415 RSUs; reported acquisition price: $0.00.
- Shares owned after transaction: Not specified in the provided filing excerpt.
- Footnote: The RSUs were granted under the 2022 Equity Incentive Plan and convert one-for-one into common stock. Vesting: 50% on Jan 31, 2027 and 50% on Jan 31, 2028 (see F1).
- Timeliness: Filing does not indicate lateness; transaction dated Jan 31 and filed Feb 3, 2026.
Context
- RSU grants are compensatory awards and are different from open-market purchases or sales; they typically vest over time and therefore do not necessarily signal immediate insider buying or selling. Upon vesting the RSUs convert to shares (and may be subject to tax withholding per plan rules).
Insider Transaction Report
Form 4
Rangwala Reshma
EVP & Chief Medical Officer
Transactions
- Award
Common Stock
[F1]2026-01-31+32,415→ 61,805 total
Footnotes (1)
- [F1]Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended (the "2022 Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest as to 50% of the shares on January 31, 2027, with the remaining 50% vesting on January 31, 2028.
Signature
/s/Nancy Smith as Attorney-in-Fact for Reshma Rangwala|2026-02-03